Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E149.69 EPS (ttm)1.03 Insider Own0.50% Shs Outstand252.07M Perf Week1.12%
Market Cap38.98B Forward P/E50.27 EPS next Y3.08 Insider Trans-49.68% Shs Float250.98M Perf Month1.69%
Income259.50M PEG2.20 EPS next Q0.31 Inst Own98.70% Short Float1.33% Perf Quarter-6.91%
Sales2.13B P/S18.29 EPS this Y80.10% Inst Trans0.55% Short Ratio2.21 Perf Half Y31.42%
Book/sh6.75 P/B22.91 EPS next Y89.41% ROA8.80% Target Price179.44 Perf Year86.48%
Cash/sh6.62 P/C23.36 EPS next 5Y68.07% ROE19.40% 52W Range71.46 - 167.85 Perf YTD109.90%
Dividend- P/FCF64.94 EPS past 5Y-39.40% ROI-0.30% 52W High-9.24% Beta1.67
Dividend %- Quick Ratio3.30 Sales past 5Y3.80% Gross Margin89.20% 52W Low113.20% ATR3.13
Employees2150 Current Ratio3.50 Sales Q/Q26.10% Oper. Margin16.20% RSI (14)44.36 Volatility2.26% 2.09%
OptionableYes Debt/Eq0.34 EPS Q/Q127.10% Profit Margin12.20% Rel Volume0.79 Prev Close154.63
ShortableYes LT Debt/Eq0.33 EarningsOct 25 AMC Payout0.00% Avg Volume1.51M Price152.35
Recom1.80 SMA20-0.35% SMA50-1.00% SMA20023.85% Volume657,917 Change-1.47%
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Jan-26-17Reiterated Stifel Buy $108 → $100
Dec-15-16Initiated Oppenheimer Perform
Oct-24-16Downgrade H.C. Wainwright Buy → Neutral $85
Sep-15-16Reiterated Stifel Buy $105 → $109
Sep-13-16Initiated Raymond James Mkt Perform
Oct-23-17 12:00PM  A Foolish Take: The Best-Performing S&P 500 Stock This Year Motley Fool
09:02AM  Zacks.com highlights: Vertex Pharmaceuticals, Lululemon Athletica, Sanderson Farms and Farmers & Merchants Bancorp Zacks
08:32AM  Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families Business Wire
Oct-20-17 10:49AM  Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings? Zacks
10:29AM  4 of the Most Efficient Stocks to Buy Now Zacks
Oct-18-17 09:55AM  Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals Zacks
08:07AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Oct-17-17 03:55PM  Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks Zacks
10:54AM  This Pharma Stock Is Up 111% and Investors Are Wondering What's Next Bloomberg
06:15AM  Vertex Announces 10-Year, $500 Million Corporate Giving Commitment Business Wire
Oct-16-17 04:01PM  Vertex to Announce Third Quarter 2017 Financial Results on October 25 Business Wire
02:31PM  Wall Street analysts expect gains of up to 64% on their favorite health-care stocks MarketWatch
Oct-15-17 07:03AM  The 1 Stock You've Been Overlooking for Your Roth IRA Motley Fool
Oct-13-17 09:17AM  Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day Zacks
07:00AM  Bull of the Day: Vertex Pharmaceuticals (VRTX) Zacks
Oct-12-17 10:31AM  Pres Trump believes he has the cure for Obamacare Yahoo Finance Video
Oct-10-17 12:20PM  Vertex Pharmaceuticals, Inc. Value Analysis (NASDAQ:VRTX) : October 10, 2017 Capital Cube
11:00AM  Amgen Label Expansion Application for Prolia Accepted by FDA Zacks
10:01AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings Zacks
08:30AM  Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX) Zacks
Oct-09-17 10:20AM  Forget Teva (TEVA), Buy These 5 Drug Stocks Instead Zacks
08:14AM  Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : October 9, 2017 Capital Cube
Oct-04-17 07:44AM  Alexion on the Street: Analyst Recommendations in October Market Realist
Oct-03-17 09:30AM  3 Top-Ranked Big Biotech Stocks to Buy Now Zacks
Sep-29-17 08:56AM  3 Reasons To Like Vertex Pharma Shares Benzinga
Sep-28-17 06:02AM  Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis? Motley Fool
Sep-27-17 02:07PM  Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson Zacks
Sep-25-17 07:04AM  3 Highest-Growth Stocks in the Market Today Motley Fool
Sep-24-17 09:09AM  3 Monster Biotech Stocks in the Making Motley Fool
Sep-22-17 07:30PM  Vertex Pharmaceuticals: Going From 'Crisis' To Blockbuster Investor's Business Daily
Sep-21-17 04:01PM  Vertex to Present at the Leerink Partners Roundtable Series on September 27 Business Wire
08:13AM  Vertex's Rocky September Causes Vetr To Urge Sell Benzinga
Sep-19-17 10:50AM  Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference Business Wire
07:08AM  The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard Zacks
Sep-18-17 02:12PM  Both stocks and bonds could drop during the next bear market: trader Yahoo Finance
12:28PM  Analysts have raised, or lowered, their price targets the most on these U.S. stocks MarketWatch
11:42AM  5 Top-Performing Stocks Driving S&P 500 ETF Higher Zacks
Sep-13-17 10:05AM  4 Biotech Stocks for the Long-Term InvestorPlace
Sep-12-17 08:04AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
08:03AM  2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term Motley Fool
Sep-11-17 05:29PM  Top Biotech Stock Near Buy Zone After FDA Drug Approval Investor's Business Daily
04:08PM  Apple's iPhone Launch; 4 Top Stocks Near Buys: Tuesday's Investing Action Plan Investor's Business Daily
10:09AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Sep-07-17 04:01PM  Vertex to Present at the Morgan Stanley Healthcare Conference on September 11 Business Wire
Sep-06-17 01:31PM  Vertex Pharmaceuticals Could Be Headed Higher Once Again TheStreet.com
08:29AM  Vertex Pharma surges 1% after news of new CFO MarketWatch
08:05AM  Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer Business Wire
07:37AM  Behind Bioverativs Analyst Recommendations This September Market Realist
Sep-05-17 03:34PM  3 Growth Stocks for the 21st Century Motley Fool
12:31PM  Sarepta: Time to Buy? Barrons.com
11:50AM  Alexion: Quite a Comeback Barrons.com
Sep-01-17 11:29AM  4 Biotech Stocks That More Than Doubled This Year Zacks
09:07AM  How Are Orkambi and Kalydeco Positioned after 2Q17? Market Realist
07:38AM  Vertex Presented Successful Results for Cystic Fibrosis Treatment Market Realist
Aug-31-17 02:35PM  Vertex Saw Successful Results from VX-440 Phase 2 Study Market Realist
01:06PM  How Vertex Pharmaceuticals Performed in 2Q17 Market Realist
11:14AM  What Analysts Recommend for Vertex Pharmaceuticals after 2Q17 Market Realist
Aug-29-17 02:15PM  3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock InvestorPlace
01:59PM  Analyst Recommendations for Regeneron Pharmaceuticals in August Market Realist
08:06AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
05:00AM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors InvestorPlace
03:34AM  Vertex Pharmaceuticals (VRTX) Down 5.2% Since Earnings Report: Can It Rebound? Zacks
Aug-28-17 08:05AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Aug-25-17 10:51AM  Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S. Zacks
Aug-24-17 11:30AM  Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA Business Wire
10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
Aug-23-17 12:30PM  Lab-made "mini organs" helping doctors treat cystic fibrosis Associated Press
03:32AM  Lab-made "mini organs" helping doctors treat cystic fibrosis Associated Press
Aug-22-17 08:06AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Aug-21-17 02:19PM  Gilead: Where's the Urgency? Barrons.com
01:31PM  Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive InvestorPlace
08:06AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Aug-17-17 09:03AM  The 3 Best Stocks in Healthcare Motley Fool
Aug-16-17 08:00AM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
Aug-15-17 05:20PM  ETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017 Capital Cube
04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 10:25AM  Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isnt Worth the Risk InvestorPlace
Aug-13-17 08:00AM  Edited Transcript of VRTX earnings conference call or presentation 26-Jul-17 9:15pm GMT Thomson Reuters StreetEvents
Aug-11-17 11:44AM  CD 2016-CD1 Mortgage Trust -- Moody's Affirms Eight Classes of CD 2016-CD1 Moody's
08:04AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Aug-10-17 08:04AM  IHS Markit Score downgrades Vertex Pharmaceuticals Inc to 64 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
09:45AM  For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another? Forbes
Aug-04-17 08:01PM  Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings Motley Fool
Aug-03-17 07:45PM  Why Vertex Pharmaceuticals Skyrocketed 17.8% in July Motley Fool
09:46AM  Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons InvestorPlace
07:10AM  Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis ACCESSWIRE
Aug-02-17 12:35PM  Vertexs latest FDA nod could boost sales by $150M: analyst American City Business Journals
08:32AM  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote Zacks
Aug-01-17 12:09PM  Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
08:01AM  FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations Business Wire
Jul-28-17 10:00AM  Vertex Pharmaceuticals Incorporated Chugs Along Motley Fool
Jul-27-17 04:50PM  Vertex Pharmaceuticals: Looking East, West and to the Quants TheStreet.com
04:29PM  Biotech Fever Cools As These Players Dip On Longer-Term Views Investor's Business Daily
02:50PM  Vertex Pharmaceuticals: Looking East, West and to the Quants TheStreet.com
09:54AM  Zacks.com featured highlights: Farmers & Merchants Bancorp, Advanced Energy Industries, NVR, Vertex Pharmaceuticals and Sanderson Farms Zacks
08:59AM  Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales Zacks
08:06AM  J.P. Morgan Elevates Price Targets on Gilead Sciences, Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX) After Glowing 2Q Performance SmarterAnalyst
08:00AM  Trending: Corn Falls Due to Heavy Northeast Rains ETF Database
Jul-26-17 10:55PM  Vertex tops Street 2Q forecasts Associated Press
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chodakewitz JeffreyEVP GMDA, CMOOct 16Option Exercise96.871,718166,423116,142Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Option Exercise96.872,125205,849118,013Oct 18 05:41 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 16Sale155.191,718266,610114,424Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Sale155.612,125330,671115,888Oct 18 05:41 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86630,934Oct 16 04:59 PM
Parini MichaelEVP, CL&AOOct 12Sale152.932,125324,97628,809Oct 16 04:59 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 02Option Exercise73.513,437252,654117,861Oct 04 05:01 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 02Sale151.643,437521,198114,424Oct 04 05:01 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 31Option Exercise91.051,796163,526107,807Sep 05 04:42 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 31Sale160.001,796287,360106,011Sep 05 04:42 PM
SMITH IAN FEVP, CFO & COOAug 07Option Exercise77.314,250328,568120,138Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Option Exercise77.314,250328,568125,367Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Option Exercise77.311,28999,65317,923Aug 09 04:38 PM
SMITH IAN FEVP, CFO & COOAug 07Sale155.394,250660,415115,888Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Sale152.884,250649,740121,117Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Sale152.881,289197,06216,634Aug 09 04:38 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Option Exercise109.143,594392,249118,018Aug 04 04:42 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59231,139Aug 04 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise109.144,250463,845125,367Aug 04 04:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale155.724,250661,810121,117Aug 04 04:53 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Sale154.193,594554,149114,424Aug 04 04:42 PM
Parini MichaelEVP, CL&AOAug 03Sale155.722,330362,82828,809Aug 04 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Option Exercise91.051,796163,526116,220Aug 04 04:42 PM
SMITH IAN FEVP, CFO & COOAug 02Option Exercise91.052,155196,213118,043Aug 04 04:48 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,923Aug 04 04:36 PM
SMITH IAN FEVP, CFO & COOAug 02Sale154.172,155332,236115,888Aug 04 04:48 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Sale154.131,796276,811114,424Aug 04 04:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale151.801,289195,67016,634Aug 04 04:36 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Option Exercise83.362,125177,140123,242Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Option Exercise83.3686071,69017,494Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Option Exercise83.362,125177,140118,013Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Option Exercise45.1111,063499,052268,455Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Sale152.992,125325,104121,117Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Sale152.99860131,57116,634Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Sale152.882,125324,865115,888Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Sale152.8111,0631,690,552257,392Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Option Exercise131.892,125280,266133,592Jul 21 07:58 PM
Sachdev AmitEVP, CROJul 21Sale160.788,6251,386,69190,710Jul 21 08:07 PM
SMITH IAN FEVP, CFO & COOJul 21Sale160.7210,3501,663,413115,888Jul 21 08:09 PM
Silva Paul MSVP & Corp ControllerJul 21Sale161.913,437556,49016,634Jul 21 08:10 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 21Sale160.736,9001,109,022114,424Jul 21 08:02 PM
LEIDEN JEFFREY MCEO & PresidentJul 21Sale160.7432,2505,184,008257,392Jul 21 08:04 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Sale161.2212,4752,011,271121,117Jul 21 07:58 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 19Option Exercise107.2589,4009,587,718220,867Jul 21 07:58 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Option Exercise84.4928,9792,448,338134,990Jul 21 08:00 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 19Option Exercise107.1438,6464,140,487161,157Jul 21 08:02 PM
Parini MichaelEVP, CL&AOJul 19Option Exercise89.4810,829968,97039,638Jul 21 08:05 PM
LEIDEN JEFFREY MCEO & PresidentJul 19Option Exercise46.56184,3748,584,824474,016Jul 21 08:04 PM
Sachdev AmitEVP, CROJul 19Option Exercise77.3120,0001,546,200119,335Jul 21 08:07 PM
Silva Paul MSVP & Corp ControllerJul 19Option Exercise75.9140,0063,036,87060,077Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 19Option Exercise84.11123,40010,379,726249,638Jul 21 08:09 PM
Silva Paul MSVP & Corp ControllerJul 19Sale161.0040,0066,440,96620,071Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 19Sale161.00123,40019,867,400126,238Jul 21 08:09 PM
Sachdev AmitEVP, CROJul 19Sale161.0020,0003,220,00099,335Jul 21 08:07 PM
Parini MichaelEVP, CL&AOJul 19Sale161.0010,8291,743,46928,809Jul 21 08:05 PM
LEIDEN JEFFREY MCEO & PresidentJul 19Sale161.00184,37429,684,214289,642Jul 21 08:04 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 19Sale161.0039,8336,413,113121,324Jul 21 08:02 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Sale161.0028,9794,665,619106,011Jul 21 08:00 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 19Sale161.5489,40014,441,830131,467Jul 21 07:58 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 17Option Exercise96.8757355,507123,084Jul 19 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 17Sale129.8557374,402122,511Jul 19 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 03Option Exercise73.513,438252,727125,949Jul 06 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 03Sale127.803,438439,379122,511Jul 06 04:45 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 21Option Exercise96.875,157499,559127,668Jun 23 04:08 PM
Silva Paul MSVP & Corp ControllerJun 21Option Exercise83.362,577214,81922,648Jun 23 04:10 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 21Sale132.875,157685,211122,511Jun 23 04:08 PM
Silva Paul MSVP & Corp ControllerJun 21Sale133.362,577343,66920,071Jun 23 04:10 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 05Option Exercise72.147,500541,050113,511Jun 05 06:10 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 05Sale130.007,500975,000106,011Jun 05 06:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 02Option Exercise80.6757,3754,628,505188,842Jun 05 06:06 PM
LEIDEN JEFFREY MCEO & PresidentJun 02Option Exercise33.63147,1014,947,163436,743Jun 05 06:03 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 02Sale129.0257,3757,402,523131,467Jun 05 06:06 PM
LEIDEN JEFFREY MCEO & PresidentJun 02Sale129.50147,10119,049,580289,642Jun 05 06:03 PM
Lee YuchunDirectorJun 02Sale128.441,323169,9264,847Jun 05 05:56 PM
Bhatia Sangeeta N.DirectorJun 02Sale128.441,176151,0453,953Jun 05 05:07 PM
Sachdev AmitEVP, CROJun 01Option Exercise51.7530,5001,578,375129,835Jun 05 06:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 01Option Exercise53.7413,594730,542145,061Jun 05 06:06 PM
SMITH IAN FEVP, CFO & COOJun 01Option Exercise43.9998,5534,334,887224,791Jun 05 06:05 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 01Option Exercise96.875,155499,365127,666Jun 05 06:07 PM
Silva Paul MSVP & Corp ControllerJun 01Option Exercise77.313,867298,95823,938Jun 05 06:09 PM
Silva Paul MSVP & Corp ControllerJun 01Sale127.313,867492,30820,071Jun 05 06:09 PM
Chodakewitz JeffreyEVP GMDA, CMOJun 01Sale126.875,155654,015122,511Jun 05 06:07 PM
Sachdev AmitEVP, CROJun 01Sale125.0030,5003,812,50099,335Jun 05 06:08 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 01Sale124.0013,5941,685,656131,467Jun 05 06:06 PM
SMITH IAN FEVP, CFO & COOJun 01Sale124.0098,55312,220,572126,238Jun 05 06:05 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale114.3718120,701106,011May 17 04:25 PM
SMITH IAN FEVP, CFO & COOMay 15Sale114.9229433,786126,238May 17 04:24 PM
Sachdev AmitEVP, CROMay 15Sale114.3711613,26799,335May 17 04:23 PM
Silva Paul MSVP & Corp ControllerMay 15Sale114.6427131,06720,071May 17 04:21 PM
Chodakewitz JeffreyEVP GMDA, CMOMay 02Option Exercise91.058,979817,538131,490May 04 08:51 AM
Chodakewitz JeffreyEVP GMDA, CMOMay 02Sale121.058,9791,086,908122,511May 04 08:51 AM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 28Option Exercise45.1128,3201,277,515159,567May 02 05:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOApr 28Option Exercise63.147,500473,550113,511May 02 05:18 PM
LEIDEN JEFFREY MCEO & PresidentApr 28Option Exercise31.51140,0344,412,253446,679Apr 28 04:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 28Sale119.5028,3203,384,240131,247May 02 05:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOApr 28Sale120.007,500900,000106,011May 02 05:18 PM
LEIDEN JEFFREY MCEO & PresidentApr 28Sale119.50157,20018,785,400289,479Apr 28 04:44 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 05Option Exercise73.518,021589,624130,532Apr 07 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 05Sale114.008,021914,394122,511Apr 07 04:09 PM
Chodakewitz JeffreyEVP GMDA, CMOApr 03Option Exercise73.512,291168,411124,802Apr 05 04:55 PM